Fed. Cir. Vacates $20M Verdict in Rasmussen v. DePuy: Patent Owne

Note: This article is based on real case information and is intended for general informational purposes, not legal advice.

Patent litigation usually sells itself as a drama about invention, copying, and a very expensive argument over who borrowed whose ideas. But in Rasmussen Instruments, LLC v. DePuy Synthes Products, Inc., the Federal Circuit reminded everyone that before a patent owner can collect a dime, win an injunction, or enjoy a victory lap, it needs something even less glamorous and far more important: actual ownership of the patent rights at the moment the lawsuit is filed.

That may sound obvious, like saying a pilot should probably know where the airplane is going before takeoff. Yet this case proves that chain-of-title problems can lurk for years, then show up at the worst possible moment with the legal equivalent of a wrecking ball. A Massachusetts jury had awarded Rasmussen Instruments $20 million after finding willful infringement of one patent tied to knee replacement technology. The district court later added prejudgment interest and entered a permanent injunction. From the outside, that looked like a major patent owner win. On appeal, though, the Federal Circuit vacated the judgment and sent the case back with instructions to dismiss for lack of jurisdiction.

Why? Because the court concluded Rasmussen Instruments did not own either asserted patent when it sued DePuy in 2020. In patent law, that is not a technical hiccup. That is the trapdoor.

What the Rasmussen v. DePuy fight was about

The dispute centered on orthopedic surgical technology used during knee replacement procedures. The patents at issue, U.S. Patent Nos. 9,492,180 and 10,517,583, involve arthroplasty systems and methods for aligning and tensioning a knee prosthesis. In plain English, we are talking about instruments meant to help surgeons position components properly and balance the knee during surgery. In medtech, that is not small potatoes. That is the kind of operating-room functionality companies care about deeply because it touches both clinical outcomes and commercial value.

Dr. G. Lynn Rasmussen, an orthopedic surgeon, developed what the record describes as the “Zen Instrument.” He later sought patent protection, and Rasmussen Instruments sued DePuy in 2020, alleging that DePuy’s Attune Balanced Sizer infringed. The lawsuit claimed the DePuy product used Rasmussen’s patented approach to adjusting ligament tension and alignment during knee arthroplasty. After a fourteen-day trial in 2022, the jury found DePuy had willfully infringed the ’180 patent, did not infringe the ’583 patent, and failed to prove either patent invalid.

That verdict alone made the case notable. A $20 million award in a medical device patent case is real money, and the willfulness finding gave the plaintiff room to argue for even more. The district court did not award treble damages or attorney fees, but it did grant prejudgment interest and a permanent injunction against the infringing product. For Rasmussen, it looked like a hard-earned courtroom triumph. For DePuy, it was appeal time.

The Federal Circuit’s reversal was about standing, not gadget geekery

Here is what makes the ruling so interesting: the Federal Circuit did not blow up the verdict because it loved DePuy’s noninfringement arguments or because it suddenly decided the patents were invalid. Instead, the court treated standing as the threshold issue. In other words, before anyone debates infringement, remedies, or who owes whom a truckload of cash, the plaintiff must prove it had the right to sue in the first place.

And in patent cases, that usually means the plaintiff must be the patentee or hold a valid assignment when the complaint is filed. No assignment, no standing. No standing, no jurisdiction. No jurisdiction, no case. It is a brutal sequence, but a very clean one.

The appellate court focused on a 2006 agreement between Dr. Rasmussen and Wright Medical. That agreement used classic present-tense assignment language: Dr. Rasmussen “hereby assigns” his rights in the relevant know-how, inventions, and related intellectual property. Lawyers love to obsess over wording, and this case shows why. The Federal Circuit treated that phrase as immediate, automatic, and self-executing. Translation: the rights moved then and there. No later paperwork parade was needed to make the transfer real.

The opinion also concluded that the 2006 deal swept broadly enough to cover the technology tied to the asserted patents, including later improvements and related rights. The court pointed to the agreement’s structure, the definition of the licensed product, and testimony connecting that product to Rasmussen’s Zen Instrument. Once the panel reached that conclusion, the ownership path became much less friendly to the plaintiff.

Why the 2013 unwind did not save Rasmussen

Rasmussen argued that later agreements from 2013, executed when the business relationship with Wright was being unwound, effectively restored ownership. That argument had understandable emotional appeal. Many business divorces end with each side believing it took its own toys home. The problem is that patent ownership does not work on vibes, assumptions, or the legal equivalent of “you know what we meant.”

The Federal Circuit found that the 2013 settlement and license agreements did not expressly assign patent rights back to Dr. Rasmussen. They amended parts of the earlier arrangement, and they removed references to the “Licensed Product” in important sections. But the court emphasized that none of those later agreements actually said Wright was transferring patent ownership back. That missing step turned out to be everything.

This is where patent cases become a little like real estate closings. You may feel like the house is yours. You may have the keys. You may even be standing in the kitchen arguing about paint colors. But if the deed never got transferred, the legal picture can be painfully different. The Federal Circuit treated the 2020 assignment from Dr. Rasmussen to Rasmussen Instruments the same way: it was ineffective because he could not assign rights he did not own.

The lesson for patent owners: chain of title is not boring paperwork

If this case has a villain, it is not necessarily DePuy. It may be the quiet pile of contract language that companies often treat as back-office clutter until litigation makes it front-page news. Patent ownership and chain of title are not administrative side quests. They are core assets. A patent can look powerful on paper, sit in a portfolio, appear in licensing talks, and still become unenforceable in court if the ownership trail is broken.

That matters even more in industries like medtech, where innovation often moves through a messy web of inventors, consultants, distributors, licensors, development partners, and later spinouts. A surgeon collaborates with a device company. A company changes names or gets acquired. A settlement adjusts prior obligations. Someone forms an LLC. Then, years later, litigation asks a simple but devastating question: who actually owned the patents on filing day?

In Rasmussen v. DePuy, the Federal Circuit’s answer wiped out a verdict that had already survived a jury trial and post-trial motions. That outcome should put every patent owner, startup founder, and in-house IP lawyer on alert. If you are planning to enforce a patent, you should confirm not only who is listed at the Patent Office, but also whether the underlying contracts really transferred rights the way you think they did. Patent office records can tell part of the story. The contracts usually tell the part that hurts.

Why this ruling matters even though it is nonprecedential

The opinion is nonprecedential, which means it does not carry the formal weight of a precedential Federal Circuit decision. Still, that should not lull anyone into shrugging it off. Nonprecedential does not mean unimportant. In practical terms, the ruling is a sharp warning shot because it applies familiar patent standing principles in a way every litigator and deal lawyer can understand.

The court leaned on settled ideas: standing is required at filing, assignments must be in writing, and present-tense assignment language usually transfers rights immediately. Those are not exotic concepts pulled from some dusty procedural basement. They are recurring rules in patent litigation. What makes Rasmussen memorable is how clearly it shows the cost of ignoring them. A plaintiff can win on infringement at trial and still lose the entire war if ownership was wrong from the start.

There is also a strategic takeaway for defendants. Ownership challenges can feel secondary when a case is dominated by infringement experts, technical diagrams, and product comparisons. This ruling shows they are anything but secondary. If there is a genuine chain-of-title weakness, it may be the cleanest path to a knockout punch.

Where the case stands now

As of the latest widely reported developments, the Federal Circuit’s October 2025 ruling vacated the judgment and instructed the district court to dismiss the action for lack of jurisdiction. Rasmussen later sought panel rehearing and rehearing en banc, but that effort was denied in late December 2025. That leaves the appellate decision standing, and the $20 million verdict remains erased rather than merely reduced or trimmed around the edges.

For DePuy, the appellate result transformed a serious litigation loss into a jurisdictional win. For Rasmussen, it turned a courtroom victory into a case study in how patent enforcement can collapse before the merits ever get the final word. For everyone else watching, it supplied a clear message: ownership is not a housekeeping detail. It is the front door key.

Practical examples for businesses and inventors

Example 1: The founder who “always thought the patents were mine”

A medical inventor works with a manufacturer, signs a development agreement, then leaves a few years later. He later forms a new company and assigns patents into it. If the original agreement used present-tense assignment language and covered improvements or later variations, his new company may have just received a beautifully framed legal illusion.

Example 2: The acquirer who checks the USPTO but not the contracts

A buyer sees that a patent is listed in the seller’s name and assumes the ownership story is clean. But buried in old consulting, settlement, or license agreements is language showing the rights moved elsewhere long ago. Congratulations: the buyer may have purchased a litigation headache with a ribbon on top.

Example 3: The plaintiff who waits too long to fix title

Sometimes parties realize a title problem exists and try to patch it after filing suit. Courts are often unforgiving about that move when standing was missing at the outset. A cleanup document signed too late may be useful for future rights, but it may not resurrect a case that was dead on arrival.

Experiences related to the topic: what this kind of case feels like in the real world

If you spend enough time around patent enforcement, you start to notice a recurring emotional arc. The inventor remembers the spark of the original idea with crystal clarity. The company remembers the money it spent developing, testing, refining, and commercializing that idea. The lawyers arrive later and ask everyone to produce contracts from fifteen or twenty years ago. That is usually the moment the room gets very quiet.

Cases like Rasmussen v. DePuy feel painfully familiar because they expose the gap between commercial ownership and legal ownership. In ordinary business life, people often act as if the inventor, the startup, or the operating company “obviously” owns the technology. They present it at conferences, reference it in pitch decks, discuss licensing, and maybe even list it in corporate materials. For years, nobody stops the music to ask whether an old consulting agreement used “will assign” language or “hereby assigns” language. Then litigation starts, and suddenly the grammar from a long-forgotten contract becomes more important than the swagger in the complaint.

From the inventor side, this kind of dispute can feel deeply unfair. The inventor may sincerely believe the technology is his life’s work, because in a personal sense it is. He may have created the concepts, refined the tools, defended the ideas, and watched another company profit from similar products. But patent litigation is not a memoir contest. It is a rights contest. Courts care less about who feels closest to the invention and more about who holds the enforceable paper trail.

From the company side, the experience is different but just as intense. In-house counsel and business leaders often learn the hard way that IP diligence is not a one-time checklist item from the financing round three CEOs ago. It is ongoing maintenance. When ownership documents are incomplete, inconsistent, or too clever for their own good, they do not merely create abstract risk. They distort valuation, weaken licensing leverage, and can vaporize a litigation win that took years and millions of dollars to build.

Litigators, meanwhile, know the special frustration of seeing a case rise or fall on something that has almost nothing to do with the glamour of trial themes. You can spend months preparing experts, claims charts, demonstratives, and damages models, only to discover that the most important exhibit in the whole case is an old agreement sitting quietly in a binder like a cobra in a filing cabinet.

That is why the real experience lesson from Rasmussen is not just “draft better contracts.” It is broader. Treat patent ownership like a living asset. Audit it. Reconfirm it after restructurings. Reconfirm it after settlements. Reconfirm it before licensing talks. And absolutely re-confirm it before filing suit. Because no patent owner wants to win a $20 million verdict, celebrate, and then learn that the lawsuit had a jurisdictional banana peel under it the whole time.

Conclusion

The Federal Circuit’s decision in Rasmussen v. DePuy is a vivid reminder that patent enforcement begins long before a complaint is filed and long before a jury hears anything about infringement. It begins with ownership. In this case, Rasmussen had a jury verdict, a willfulness finding, prejudgment interest, and an injunction. What it did not have, according to the appellate court, was a valid ownership position when the case started. That missing element erased the rest.

For patent owners, investors, medtech companies, and inventors, the takeaway is blunt: if your chain of title is shaky, your lawsuit may be too. And unlike a typo in a press release or a bad coffee choice before oral argument, that is not the kind of problem you laugh off later. The safest move is simple, if not glamorous: read the agreements, verify the assignments, and make sure the patent owner is truly the patent owner before stepping into court.